文献速递帕金森病与运动障碍认知障碍与痴呆

脑脊液α-突触核蛋白种子扩增与皮肤免疫荧光检测:临床应用、研究机会与知识空白

CSF α-Synuclein Seed Amplification Assays and Skin Immunofluorescence: Clinical Applications, Research Opportunities, and Knowledge Gaps.
PubMed 文献 · Neurology · 2026-01-13

该综述汇总了脑脊液α-突触核蛋白种子扩增检测(CSF aSyn-SAA)与皮肤磷酸化α-突触核蛋白免疫荧光(skin aSyn-IF)在突触核蛋白病中的已发表证据,并讨论其在临床试验中的潜在应用。文章指出这两种检测已可在非研究场景商业化使用,但作为诊断工具的效用与局限尚需明确,呼吁制定正式临床使用指南。

要点

  • CSF aSyn-SAA与皮肤aSyn-IF分别检测病理性aSyn种子和磷酸化aSyn聚集体。
  • 在帕金森病、路易体痴呆和多系统萎缩等突触核蛋白病中阳性率高。
  • 在嗅觉减退和REM睡眠行为障碍等风险人群中也有高阳性率记录。

核心结论

  • CSF aSyn-SAA和皮肤aSyn-IF可检测体内病理性aSyn,是神经退行性疾病领域的重大进展。
  • 两种检测在研究场景和临床护理中具有多种潜在应用,但作为诊断工具的效用与局限需进一步明确。
  • 作者呼吁为已商业化的CSF aSyn-SAA和皮肤aSyn-IF检测制定正式临床使用指南。

研究设计与样本

  • 综述类文章,汇总已发表的CSF aSyn-SAA和皮肤aSyn-IF检测证据,并讨论其在临床试验中的潜在研究应用。

主要发现

  • CSF aSyn-SAA检测病理性aSyn种子,皮肤aSyn-IF检测磷酸化aSyn聚集体。
  • 在帕金森病、路易体痴呆和多系统萎缩患者中,两种检测均显示高阳性率。
  • 在嗅觉减退和REM睡眠行为障碍等未来aSyn相关疾病风险人群及其他场景中,也记录到高阳性率。

临床怎么用

  • CSF aSyn-SAA和皮肤aSyn-IF检测已可在非研究场景商业化供临床医生使用。
  • 临床使用时需注意其当前效用与局限,并关注正式临床使用指南的制定进展。

局限性

  • 文章指出该领域仍存在关键知识空白,并探讨了与这些检测相关的新兴发展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of biomarkers capable of reliably detecting pathologic forms of α-synuclein (aSyn) in vivo marks a significant step forward in the field of neurodegeneration. Over the recent years, CSF aSyn seed amplification assays (aSyn-SAA) and skin biopsy phospho-aSyn immunofluorescence (skin aSyn-IF) testing were developed that detect pathologic aSyn seeds and phosphorylated aSyn aggregates, respectively, in patients with synucleinopathies, which include Parkinson disease, dementia with Lewy bodies, and also multiple system atrophy. High rates of positivity have also been documented in research participants at a risk of developing future aSyn-related disease (e.g., hyposmia and REM sleep behavior disorder), as well as other contexts. These assays have numerous potential applications in research settings and clinical care. Here, we review the currently published evidence supporting CSF aSyn-SAA and skin aSyn-IF testing and discuss their potential research applications in clinical trials. As CSF aSyn-SAA and skin aSyn-IF testing is now commercially available to clinicians in nonresearch settings, we also explore their current utility and limitations as diagnostic tools and call for the development of a formal clinical use guidelines. We also highlight where critical knowledge gaps remain and explore emerging developments related to these assays.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Coughlin DG, Adler CH, Barbosa W, et al. CSF α-Synuclein Seed Amplification Assays and Skin Immunofluorescence: Clinical Applications, Research Opportunities, and Knowledge Gaps. Neurology. 2026. PMID: 41529231. doi:10.1212/WNL.0000000000214648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。